Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

GO BACK TO PRESS RELEASES & MEDIA Press Release November 7, 2024 Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting Clasp-1025, Clasp’s first-in-class T cell engager (TCE) targeting mutant p53, demonstrates selectivity, sensitivity and activity across preclinical models Data support the clinical development of CLSP-1025, expected to be the first absolutely tumor-specific TCE in clinical development CAMBRIDGE, MA and ROCKVILLE, MD – November 07, 2024 – Clasp Therapeutics, a biotechn